Last10K.com

Cortex Pharmaceuticals Inc (RSPI) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2014

Respirerx Pharmaceuticals Inc.

CIK: 849636 Ticker: RSPI
Document and Entity Information (USD $)
12 Months Ended
Dec. 31, 2014
Mar. 24, 2015
Jun. 30, 2014
Document And Entity Information      
Entity Registrant Name CORTEX PHARMACEUTICALS INC/DE/    
Entity Central Index Key 0000849636    
Document Type 10-K    
Document Period End Date Dec. 31, 2014    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Entity a Well-known Seasoned Issuer No    
Entity a Voluntary Filer No    
Entity's Reporting Status Current Yes    
Entity Filer Category Smaller Reporting Company    
Entity Public Float     $ 4,232,000dei_EntityPublicFloat
Entity Common Stock, Shares Outstanding   240,318,062dei_EntityCommonStockSharesOutstanding  
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2014    

View differences made from one year to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..

Continue

Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Stockholders' Deficiency
Consolidated Statement Of Stockholders' Deficiency (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (parenthetical)
Consolidated Statements Of Operations
Consolidated Statements Of Operations (parenthetical)
Commitments And Contingencies
Commitments And Contingencies (details Narrative)
Income Taxes
Income Taxes (details Narrative)
Income Taxes (tables)
Income Taxes - Reconciliation Of Income Tax Rate Federal Statutory Rate And Effective Tax Rate (details)
Income Taxes - Schedule Of Deferred Tax Assets (details)
Notes Payable
Notes Payable (details Narrative)
Notes Payable (tables)
Notes Payable - Schedule Of Convertible Notes Payable (details)
Notes Payable - Summary Of Note Payable To Related Party (details)
Organization And Business Operations
Organization And Business Operations (details Narrative)
Project Advance
Project Advance (details Narrative)
Related Party Transactions
Related Party Transactions (details Narrative)
Settlements
Settlements (details Narrative)
Stockholders' Deficiency
Stockholders' Deficiency (details Narrative)
Stockholders' Deficiency (tables)
Stockholders' Deficiency - Exercise Prices Of Common Stock Options Outstanding And Exercisable (details)
Stockholders' Deficiency - Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (details)
Stockholders' Deficiency - Schedule Of Stock Options Activity (details)
Stockholders' Deficiency - Schedule Of Warrants Activity (details)
Subsequent Events
Subsequent Events (details Narrative)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Narrative)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (details)
Summary Of Significant Accounting Policies - Summary Of Fair Value Of Option Estimated Using Black-scholes Pricing Model With Valuation Assumptions (details)
Ticker: RSPI
CIK: 849636
Form Type: 10-K Annual Report
Accession Number: 0001493152-15-001071
Submitted to the SEC: Mon Mar 30 2015 5:23:23 PM EST
Accepted by the SEC: Mon Mar 30 2015
Period: Wednesday, December 31, 2014
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rspi/0001493152-15-001071.htm